Live Quote · NASDAQVERUHealthcare· Biotechnology

Veru Inc.

$3.06 3.16%($-0.10)
TickerSpark Score
64/100
Mixed
80
Valuation
20
Profitability
55
Growth
84
Health
80
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERU research report →

52-Week Range19% of range
Low
$2.05
Current
$3.06
High
$7.33
Company Overviewwww.verupharma.com

About the company

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections.

CEO
Mitchell S. Steiner
IPO
1999
Employees
210
HQ
Miami, FL, US

Price Chart

-47.60% · this period
$6.14$4.12$2.09Jul 02Dec 31Jul 02
Valuation
Market Cap
$49.11M
P/E
-3.82
P/S
0.00
P/B
1.90
EV/EBITDA
-0.87
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-52.86%
ROIC
-49.46%
Growth & Income
Revenue
$0 · -100.00%
Net Income
$-22,726,279 · 39.88%
EPS
$-1.07 · 61.79%
Op Income
$-24,750,642
FCF YoY
-37.56%
Performance & Tape
52W High
$7.33
52W Low
$2.05
50D MA
$2.61
200D MA
$2.71
Beta
-1.13
Avg Volume
1.91M

Get TickerSpark's AI analysis on VERU

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 4, 26STEINER MITCHELL SHUSTERother604,000
May 4, 26Greco Micheleother164,000
May 4, 26Katzovitz Loren Markother102,000
May 4, 26Hyun Graceother97,000
May 4, 26Rankowitz Michael Lother100,000
May 4, 26Lu Lucyother104,000
May 4, 26BARNETTE K GARYother160,000
May 4, 26FISCH HARRYother160,000
Dec 5, 25BARNETTE K GARYother27,000
Dec 5, 25Rankowitz Michael Lother3,000
Coverage · VERU

Our VERU coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on VERU yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate VERU report →
Internal Compare

Similar companies

Peers in the same neighborhood.